Icon
+91 94997 68112
Login Register

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) - (0.8MG;200MG)

AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE None
0.8MG;200MG
Less Than $1000 mn
None None
None None
None None
AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Yes
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.